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Abstract
A stereocontrolled total synthesis of the indole diterpenoid natural product paspaline is described. 
Key steps include a highly diastereoselective enzymatic desymmetrization, substrate-directed 
epoxidation, Ireland-Claisen rearrangement, and diastereotopic group selective C–H acetoxylation 
to assemble the target with excellent stereofidelity. The route and results described herein outline 
complementary conceptual disconnections in the arena of steroid natural product synthesis.
The terpene alkaloids represent a novel subset of natural products due to their unique 
biological profiles and their departure from the archetypal steroidal motif. The veratrums, 
for example, have been implicated in prostate, pancreatic, and breast cancers and, as a result, 
have been investigated as therapeutics.1 Among these, jervine and cyclopamine have 
demonstrated marked inhibition of the hedgehog signaling pathway in vitro and are 
currently under study in clinical trials. The structurally distinct indole diterpenoids were first 
discovered from Claviceps paspali in the 1960s with the isolation of paspaline (1, Scheme 
1);2 related compounds including paspalinine,3 paspalicine,2 paxilline,4 JBIR-03,5 and 
others have since been reported.6 Derivatives of paspalinine have shown potent activity as 
potassium channel antagonists and may be useful in the treatment of glaucoma.7 JBIR-03 
exhibits anti-MRSA activity and antifungal activity against apple Valsa canker-causing 
fungus, Valsa ceratosperma.5
As part of our ongoing efforts in applying stereoselective desymmetrization methods in the 
synthesis of chiral small molecules,8,9 we identified paspaline and its related structures as 
exemplary targets for investigation. Paspaline’s core structure presents a number of 
synthetic challenges, most notably its three all-carbon quaternary centers (C4a, C12b, C12c). 
Additionally, the 2,6-cis-tetrahydropyranyl F-ring is a unique departure from the classical 
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steroid structure and requires careful synthetic planning for stereoselective assembly. These 
synthetic problems have been addressed through varied approaches since paspaline’s 
discovery, significantly via the work of Smith of co-workers.10 A number of total and partial 
synthetic studies of paspaline and related molecules have since been disclosed.11 In 
developing our synthesis plan for paspaline, we noted that the majority of these approaches 
rely on the use of the Wieland-Miescher ketone as the key intermediate for establishing the 
C4a stereocenter. While this compound represents a classical “single stereocenter” 
desymmetrization,12 we envisaged that a functionalized diketone such as 2 might set the 
stage for a more complex desymmetrization, simultaneously establishing both the C4a and 
C14a stereocenters via a biocatalytic diketone monoreduction (3) and introducing the 
functionality required for pyran assembly. In anticipation of the challenges associated with 
the late-stage creation of the C12b quaternary center,10a we hypothesized that a 
diastereotopic-group selective C–H activation on dimethyl ketone 4 or its derivatives would 
establish this critical stereocenter (5). This global and local desymmetrization approach 
would allow maximum control of stereochemical environments en route to 1.
Our synthesis commenced with establishing the key C4a–C14a stereochemical relationship 
via reductive desymmetrization of diketone 6 (Scheme 2).13 In a racemic sense, the reaction 
of this compound with NaBH4 resulted in highly stereoselective monoreduction (20:1 dr), 
giving the opposite diastereomer to that required. Fortunately, biocatalytic monoreduction of 
6 promoted by Saccharomyces cerevisiae completely overrode the inherent substrate bias, 
providing the desired (4aR,14aS)-relationship in 7 (paspaline numbering) with excellent 
diastereo- and enantioselectivity.14,15 The remaining ketone was then converted to its tosyl 
hydrazone 8 in 97% yield. The reaction of trisubstituted alkene 8 with m-CPBA followed by 
PPTS led to a stereoselective epoxidation/intramolecular etherification sequence, providing 
the cis-pyran 9 directly in 77% yield and >20:1 dr (15 g scale), and thence the silyl ether 10 
upon treatment with TBSOTf. The hydrazone was compulsory for the success of the 
sequence; when the same epoxidation was carried out on the hydroxy ketone 7, we isolated 
only the uncyclized oxirane with poor diastereoselectivity (<2:1). At this juncture, we 
speculate that the hydrazone in 8 plays a critical role in imposing a favorable reactive 
conformation on the cyclohexanol, placing the C14a hydroxyl in close proximity to the 
alkene during oxidation and subsequent ring closure. This reaction represents a rare case of a 
substrate-directed epoxidation in which the directing group is five carbons from the reaction 
center.16
Our next challenge was construction of the sterically congested D-ring in 1 (Scheme 3). We 
presumed that hydrazone 10 would provide a great deal of flexibility in investigating 
multiple approaches to D-ring assembly.17 In the iteration that ultimately proved successful, 
α-methylation of the dianion derived from 10 followed by in situ deprotonation, Shapiro 
reaction, and trapping with (HCHO)n delivered the desired primary allylic alcohol 11 in 
64% yield, which upon esterification, gave the isobutyrate 12. To assemble the C12c angular 
methyl stereocenter, we surmised that the stereo-chemical outcome of an Ireland-Claisen 
reaction of ester 12 would be strongly influenced by the axial C4a methyl group; α-approach 
of the intermediate silyl ketene acetal would provide the requisite 1,3-syn-diaxial group 
relationship.18 Indeed, enolization of 12 followed by silylation, heating, and hydrolysis gave 
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the rearrangement product 13 in 80% yield and 6:1 dr. This reaction was the only step in the 
synthesis that proceeded with less than complete stereocontrol. Esterification and 
nucleophilic methylation provided the ketone 14 in 84% yield over two steps. 
Hydroboration/oxidation of 14 proceeded with virtually complete selectivity at C4b to afford 
diol 15 in 74% yield, and subsequent global oxidation and cyclocondensation concluded D-
ring assembly (16). Hydrogenation of 16 and condensation of the ketone with O-benzyl 
hydroxylamine proceeded smoothly, giving oxime 17 in 82% yield.
Focus then turned to local desymmetrization to create the C12b all-carbon quaternary 
stereogenic center (Scheme 4). Cognizant of the fact that the lowest-energy conformation of 
17 places the C–N π-bond in plane with the equatorial methyl group, we implemented a 
directed C–H activation reaction inspired by the report of Sanford and co-workers.19,20 In 
the event, the direct application of Sanford’s conditions to oxime 17 provided the desired 
monoacetate 18 in 79% yield as a single diastereomer (1.6 g scale). This transformation 
completed assembly of the final quaternary center, which upon global deprotection and 
oxidation, gave ketoaldehyde 19 poised for synthesis completion.
From tricycle 19, there remained the challenges of establishing the C6a methine stereocenter 
and C-ring construction (Scheme 5). The needed carbon atoms were incorporated by bis-
vinylation of 19 to give diol 20,21 which, upon ring-closing metathesis, provided allylic 
alcohol 21 in 71% yield. Acid-catalyzed elimination cleanly delivered the uncon-jugated 
enone 22, which participated in a highly stereoselective catalytic hydrogenation (Pd/C), 
providing exclusively the epimeric C6a methine stereocenter. This selectivity was not 
altogether unexpected; catalytic hydrogenation of related steroidal systems have been 
documented to proceed from the convex face of the bicycle.22 To circumvent this issue, we 
envisaged reduction of the ketone in 22 might also proceed with analogous convex-face 
selectivity to give the corresponding alcohol, which would serve as a substrate for directed 
alkene reduction.23 Indeed, reduction of 22 upon treatment with LiAlH4 gave exclusively 
the (S)-hydroxyl 23 in 60% yield over two steps. The stereochemistry of this reaction is of 
note in that reduction of analogous compounds not bearing the C12a angular methyl group 
in 1 have proceeded with selectivity orthogonal to that observed in 23,22,24 giving evidence 
to the impact of this methyl group in facial preference of the ketone in 22. Catalytic 
hydrogenation of 23 using Crabtree’s catalyst and subsequent oxidation gave ketone 24 in 
86% yield over two steps with complete concave surface selectivity. To complete our 
synthesis, the Gassman indolization of 24 previously employed by Smith proved effective in 
affording paspaline (1) in 46% yield over four steps.10a,25 In addition to matching the 
reported analytical data,2a,10d an X-ray diffraction study of synthetic paspaline provided 
secondary confirmation of the final structure3c and the sense of enantioinduction imposed in 
the biocatalytic desymmetrization.26
In summary, a global and local symmetry-breaking approach to the total synthesis of the 
indole diterpenoid paspaline is reported. Central to our strategy was the implementation of a 
biocatalytic monoreduction and directed epoxidation to create the E-F bicycle, and a 
diastereotopic group selective C–H acetoxylation to assemble the C12b quaternary center. 
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The synthesis collectively demonstrates the viability of these methods in the arena of steroid 
total synthesis.
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Synthesis Plan for Paspaline
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Scheme 2. Stereocontrolled Synthesis of E- and F-Ringsa
aConditions: (a) YSC-2, H2O:DMSO (10:1), 30 °C; (b) TsHNNH2, C7H8, 70 °C; (c) m-
CPBA, CH2Cl2, 0 °C, then PPTS (10 mol %), rt; (d) TBSOTf, 2,6-lutidine, CH2Cl2, −50 °C.
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Scheme 3. D-Ring Construction and 1,3-Bis Angular Methyl Group Installationa
aConditions: (a) nBuLi, THF, −50 °C, then MeI; nBuLi, −50 °C to rt, then (HCHO)n; (b) 
isobutyric acid, DCC, DMAP (10 mol %), CH2Cl2, rt; (c) LDA, THF, −78 °C, then TMSCl, 
−78 to 75 °C; (d) TMSCHN2, MeOH:C7H8 (2:1), rt; (e) MeLi, Et2O, 0 °C to rt; (f) 
BH3·THF, THF, 50 °C, then H2O2, NaOH, 0 °C to rt; (g) (COCl)2, DMSO, CH2Cl2, −78 °C, 
then DIPEA, −78 to 0 °C; (h) KOH, THF:MeOH (1:1), 0 °C to rt; (i) H2 (1 atm), Pd/C (1.5 
mass equiv), EtOAc, rt; (j) NH2OBn·HCl, NaOAc, MeOH:H2O (5:1), 85 °C.
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Scheme 4. Local Desymmetrizing C–H Activation to Establish C12b Angular Methyl 
Stereochemistrya
aConditions: (a) Pd(OAc)2 (15 mol %), PhI(OAc)2, AcOH:Ac2O (1:1), 100 °C; (b) HCl, 
H2O:MeOH:THF:acetone (10:10:10:1), 85°C; (c) DMP, CH2Cl2, rt.
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Scheme 5. C-Ring Construction and Synthesis Completiona
aConditions: (a) vinylmagnesium bromide, CeCl3·2LiCl, THF, −78 °C; (b) Grubbs second 
gen. catalyst (20 mol %), CH2Cl2, rt; (c) TFA, CH2Cl2, 0 °C to rt; (d) LiAlH4, THF, 0 °C; 
(e) H2 (1 atm), [C8H12]IrP(C6H11)3C5H5N]PF6 (15 mol %), CH2Cl2, rt; (f) DMP, CH2Cl2, 
rt. (g) LDA, THF, 0 °C, then HMPA, Me2S2; (h) N-chloroaniline, CH2Cl2, −78 °C, then 
NEt3; (i) Raney Ni, EtOH, rt; (j) TsOH (66 mol %), CH2Cl2, 50 °C.
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